Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

You-Guang Zheng,Jin-An Wang,Long Meng,Xin Pei,Ling Zhang,Lin An,Cheng-Lin Li,Ying-Long Miao

DOI: https://doi.org/10.1016/j.ejmech.2020.112934

IF: 7.088

2021-01-01

European Journal of Medicinal Chemistry

Abstract:<p>In this study, a series of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives were designed, synthesized, and evaluated for their biological activities. Upon performing kinase assays, most of the compounds exhibited potent inhibition against JAK2/3 and Aurora A/B with the IC₅₀ values ranging from 0.008 to 2.52 μM. Among these derivatives, compound <strong>10e</strong> expressed the most moderate inhibiting activities against all the four kinases with the IC₅₀ values of 0.166 μM (JAK2), 0.057 μM (JAK3), 0.939 μM (Aurora A), and 0.583 μM (Aurora B), respectively. Moreover, most of the derived compounds exhibited potent cytotoxicity against human chronic myeloid leukemia cells K562 and human colon cancer cells HCT116, while compound <strong>10e</strong> expressed antiproliferative activities against K562 (IC_{50 =} 6.726μM). According to western blot analysis, compound <strong>10e</strong> down-regulated the phosphorylation of STAT3, STAT5, Aurora A, and Aurora B in a dose-dependent manner in K562 and HCT116 cells. Cell cycle analysis revealed that compound <strong>10e</strong> inhibited the proliferation of cells by inducing cell cycle arrest in the G2 phase. The molecular modeling suggested that compound <strong>10e</strong> could maintain a binding mode similar to the binding mode of AT9832, a common JAK 2/3 and Aurora A/B kinases multi-target kinase inhibitor. Therefore, compound <strong>10e</strong> might be a potential agent for cancer therapy deserving further research.</p>

chemistry, medicinal